Clinical Trial Update: An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD) [Phase 3]

View source ↗

Summary

This is an open-label Phase 3 trial update of NRP104 in adults with attention-deficit/hyperactivity disorder; the study is completed and results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• NRP104

Snippet

Sponsor: New River Pharmaceuticals | Conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity | Phase 3 | Status: COMPLETED | Results posted: 2009-07-17